Prometheus Biosciences, Inc.
RXDXDelisted- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001718852
Prometheus Biosciences, Inc. was delisted in 2023; its insiders filed their last Form 4 on Jun 16, 2023; 220 institutions reported holding it in 13F filings for Q1 2023, worth $4.52B in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Prometheus Biosciences, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Prometheus Biosciences, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Hassan Fred | Director | 0 | Jun 16, 2023 | 0 |
| Papa Joseph C | Director | 0Indirect | Jun 16, 2023 | 0 |
| Szela Mary T | Director | 0 | Jun 16, 2023 | 0 |
| Swain Judith L | Director | 0 | Jun 16, 2023 | 0 |
| Adams Helen C. | Director | 0 | Jun 16, 2023 | 0 |
| Marshall Keith W | Chief Financial Officer | 0 | Jun 16, 2023 | 0 |
| Stenhouse Mark | Chief Operating Officer | 0Indirect | Jun 16, 2023 | 0 |
| McKenna Mark C. | Chairman, President and CEO | 0 | Jun 16, 2023 | 0 |
| Laur James | Director | 0 | Jun 16, 2023 | 0 |
| Hendrix Martin | Director | 0 | Jun 16, 2023 | 0 |
| Cedars Sinai Intellectual Property Co | 10% Owner | 4,001,132Indirect | Mar 8, 2023 | 0 |
| Andrews Timothy K. | General Counsel | – | Nov 16, 2021 | 0 |
| Luo Allison | Chief Medical Officer | – | Nov 16, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 7, 2023 (view filing) | Apr 5 | 2 days | Marshall Keith WChief Financial Officer | SSale | −10.0K | $108.42 | −$1.08M | −50.5%9.81K after | |
| Mar 17, 2023 (view filing) | Mar 15 | 2 days | McKenna Mark C.Chairman, President & CEO | SSale | −25.0K | $116.14 | −$2.90M | −31.2%55.1K after | |
| Mar 8, 2023 (view filing) | Mar 6 | 2 days | Marshall Keith WChief Financial Officer | SSale | −10.0K | $122.13 | −$1.22M | −50.5%9.81K after | |
| Mar 8, 2023 (view filing) | Mar 8 | Same day | Cedars Sinai Intellectual Property Co10% Owner | SSale | −865.0K | $114.59 | −$99.1M | −17.8%4.00M after | |
| Mar 3, 2023 (view filing) | Mar 1-3 | 2 days | McKenna Mark C.Chairman, President & CEO | SSale | −11.3K | $125.14 | −$1.42M | −17.0%55.1K after | 2 lots |
| Feb 17, 2023 (view filing) | Feb 15 | 2 days | Marshall Keith WChief Financial Officer | SSale | −5.00K | $119.38 | −$596.9K | −33.8%9.81K after | |
| Feb 17, 2023 (view filing) | Feb 15-17 | 2 days | McKenna Mark C.Chairman, President & CEO | SSale | −63.7K | $120.82 | −$7.69M | −53.6%55.1K after | 3 lots |
| Jan 19, 2023 (view filing) | Jan 17 | 2 days | Marshall Keith WChief Financial Officer | SSale | −5.00K | $119.00 | −$595.0K | −33.8%9.81K after | |
| Jan 19, 2023 (view filing) | Jan 17 | 2 days | McKenna Mark C.Chairman, President & CEO | SSale | −25.0K | $118.99 | −$2.97M | −31.2%55.1K after |